JUPITER, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Corp. today announced a strategic collaboration aimed at advancing the development, scale-up and potential commercialization of precision-fermented bovine alpha-lactalbumin for Strive Nutrition’s FREEMILK™ platform and other Strive™ next-generation nutrition products.
The collaboration combines Dyadic’s Dapibus™ protein production platform and expertise in strain optimization and scale-up, BRIG BIO’s precision-fermentation commercialization and regulatory capabilities, and Strive’s FREEMILK™ platform and product-development and commercialization expertise. Together, the companies aim to advance the development and potential commercialization of precision-fermented alpha-lactalbumin for next-generation nutrition products.
The collaboration aims to establish an integrated pathway from protein development through scale-up, manufacturing and commercial supply. Dyadic and BRIG BIO will work together to optimize production of alpha-lactalbumin, focusing on productivity, product quality and manufacturing economics, while Strive Nutrition will evaluate protein samples for formulation, application testing and potential use in its FREEMILK™ platform and other Strive™ nutrition products. Upon successful development, scale-up, regulatory readiness, quality qualification and definitive commercial agreements, the parties are currently targeting initial commercial availability of more than 10 metric tonnes following completion of the self-affirmed GRAS process, with longer-term production scale of more than 200 metric tonnes annually.
Completion of the GRAS process for the bovine alpha-lactalbumin ingredient is currently targeted for early 2028. When the technical and commercial evaluation is successful and applicable regulatory and quality requirements are satisfied, the parties will negotiate a definitive commercial supply agreement.
“This collaboration is an important example of the commercialization strategy we are building around Dapibus,” said Joe Hazelton, President and Chief Operating Officer of Dyadic. “Our objective is not simply to demonstrate that Dapibus can produce commercially relevant proteins, but to work across the value chain to improve production economics, support scale-up and connect our technology with key partners, like BRIG BIO, that can help develop, manufacture, commercialize and ultimately use these products. Our work with BRIG BIO and the opportunity with Strive demonstrate how that model can create a pathway from technology development toward potential commercial demand.”
“We believe precision-fermented alpha-lactalbumin has the potential to become an important next-generation nutrition ingredient,” said Steven Welle, Co-founder and CEO of BRIG BIO. “BRIG BIO brings precision-fermentation development and commercialization expertise to this collaboration, and our work with Dyadic is focused on further advancing the Dapibus strain and production process toward commercially viable manufacturing for high-value markets. Combining those capabilities with Strive’s product-development expertise and potential commercial application provides a realistic framework for moving alpha-lactalbumin from development toward market.”
“Alpha-lactalbumin is an especially exciting protein because of its important role in human nutrition and its potential to help us develop better nutritional products,” said Dennis Cohlmia, Chairman and CEO of Strive Nutrition Corp. “Although alpha-lactalbumin makes up only a small percentage of the total protein in cow’s milk, it is the predominant whey protein in human breast milk. Historically, obtaining this valuable protein from conventional dairy sources has required separating it from numerous other milk proteins, creating challenges for cost-effective production at scale.
“Working with Dyadic and BRIG BIO to produce alpha-lactalbumin directly through animal-free precision fermentation represents an exciting opportunity to improve access to this highly desirable ingredient. We see significant potential to incorporate alpha-lactalbumin into our FREEMILK™ platform and new, innovative Strive™ specialized nutrition products. Bovine alpha-lactalbumin is already a major component of children’s and adult nutritional products.”
About Dyadic Applied BioSolutions
Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs.
For more information about Dyadic, please visit www.dyadic.com.
About BRIG BIO
BRIG BIO is a Netherlands-based biotechnology company transforming how high-value nutritional proteins are brought to market. Through precision fermentation and strategic partnerships across the value chain, BRIG BIO bridges breakthrough biotechnology with scalable, commercially viable protein production. Starting with bovine alpha-lactalbumin, BRIG BIO targets active and medical nutrition and other high-value nutrition markets, building a resilient, sustainable and innovative protein supply for the future.
For more information, please visit www.brig.bio.
About Strive Nutrition
Strive Nutrition Corp. is a Wichita, Kansas-based, family-founded food technology company and the first to bring a precision-fermented BLG whey protein milk to market. Its flagship brand, FREEMILK™, is a delicious everyday product with enhanced nutrition and sustainability, made with complete, animal-free BLG whey protein. FREEMILK is lactose-free, cholesterol-free, OU Pareve certified and made to taste like milk from cows. It is sold in more than 2,000 stores, including Walmart nationwide, Hy-Vee’s 270 Midwest stores and the dairy cooler at leading grocers in the New York City metro area and across the U.S., and online at Walmart.com and www.striveforbetter.com. Strive is led by Chairman and CEO Dennis Cohlmia and his family of business professionals, who bring more than 48 years of dairy and plant-based manufacturing experience, including founding KanPak Aseptic.
For more information, please visit www.striveforbetter.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of Dyadic’s clinical trial and interest in its protein production platforms, Dyadic’s research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) Dyadic’s history of net losses; (ii) market and regulatory acceptance of Dyadic’s microbial protein production platforms and other technologies; (iii) failure to commercialize Dyadic’s microbial protein production platforms or its other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) Dyadic’s capital needs; (vii) changes in global economic and financial conditions; (viii) Dyadic’s reliance on information technology; (ix) Dyadic’s dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) Dyadic’s ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause Dyadic’s actual results to differ from its current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in Dyadic’s expectations.
Contacts
Dyadic Applied BioSolutions
Joe Hazelton
jhazelton@dyadic.com
(561) 743-8333
BRIG BIO
Steven Welle
info@brig.bio
Strive Nutrition
Dennis Cohlmia, Chairman and CEO
dennis@striveforbetter.com
